Kunwoo Lee

Kunwoo Lee is the CEO and Co-founder of BreezeBio (formerly GenEdit), a Brisbane, California-based biotech company pioneering non-viral gene delivery through its proprietary NanoGalaxy platform. A Siebel Scholar and Forbes 30 Under 30 honoree who earned his PhD from UC Berkeley-UCSF Joint Program in Bioengineering, Lee co-founded GenEdit in 2016 alongside Professor Niren Murthy and fellow researcher Hyo Min Park, building out a polymer nanoparticle library of thousands of chemically distinct compounds capable of delivering diverse genetic payloads to specific tissues. The company has raised over $118 million including a $60M Series B in February 2026, struck a landmark $644M collaboration deal with Genentech, and rebranded to BreezeBio to signal its pivot from platform company to clinical-stage therapeutics developer advancing BRZ-101 for Type 1 Diabetes.